The price of Pacira BioSciences Inc (NASDAQ:PCRX) shares last traded on Wall Street fell -1.47% to $29.42.
PCRX stock price is now 4.00% away from the 50-day moving average and -4.77% away from the 200-day moving average. The market capitalization of the company currently stands at $1.37B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
#####
On December 20, 2023, Raymond James recently initiated its ‘Outperform’ rating on the stock quoting a target price of $42, while ‘TD Cowen’ rates the stock as ‘Outperform’
In other news, PACE GARY W, Director sold 90,000 shares of the company’s stock on Mar 08 ’24. The stock was sold for $2,754,000 at an average price of $30.60. Upon completion of the transaction, the Director now directly owns 22,127 shares in the company, valued at $0.65 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 07 ’24, Director PACE GARY W sold 28,257 shares of the business’s stock. A total of $870,598 was realized by selling the stock at an average price of $30.81. This leaves the insider owning 112,127 shares of the company worth $3.3 million. A total of 2.87% of the company’s stock is owned by insiders.
During the past 12 months, Pacira BioSciences Inc has had a low of $25.33 and a high of $43.50. As of last week, the company has a debt-to-equity ratio of 0.65, a current ratio of 5.81, and a quick ratio of 4.78.
The net profit margin was 10.34% and return on equity was 8.49% for PCRX. The company reported revenue of $167.12 million for the quarter, compared to $160.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 4.23 percent.
#####
#####
